Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review
Authors:
- Corrado CampochiaroCorrado Campochiaro
- Nicola FarinaNFNicola Farina
- Giacomo De LucaGLGiacomo De Luca
- Giorgia TrignaniGTGiorgia Trignani
- Alessandro TomelleriATAlessandro Tomelleri
- Marco Matucci-CerinicMMMarco Matucci-Cerinic
- Lorenzo DagnaLDLorenzo Dagna
- 15 September 2022
- journal article
- letter
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (1) , 151-153
Abstract
Antisynthetase syndrome (AS) is a rare autoimmune disorder whose treatment remains a challenge.1 In refractory cases, treatment escalation from glucocorticoids (GCs) and immunosuppressants to rituximab (RTX) is recommended.1Keywords
This publication has 10 references indexed in Scilit:
- Description and Analysis of a Novel Subtype of the Anti-Synthetase Syndrome Characterized by Frequent Attacks of Fever and Systemic Inflammation in a Single-Center Cohort StudyFrontiers in Immunology, 2021
- A case of macrophage activation syndrome in a patient with anti-synthetase syndromeOxford Medical Case Reports, 2021
- COVID-19 vaccination and antirheumatic therapyRheumatology, 2021
- Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the PandemicFrontiers in Pharmacology, 2020
- Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective StudyThe Journal of Rheumatology, 2020
- Antisynthetase syndrome and cardiac involvement: a rare associationJoint Bone Spine, 2019
- 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative InitiativeArthritis & Rheumatology, 2017
- Interleukin-1 Blockade in Acute Decompensated Heart FailureJournal of Cardiovascular Pharmacology, 2016
- Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-upAnnals of the Rheumatic Diseases, 2014
- Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case reportJoint Bone Spine, 2008